Skip to content

Microscan Dried Gram-positive Mic/Combo Panels With Daptomycin (0.03 - 16 Mcg/Ml)

by Dade Behring, Inc. 510(k)

Active United States

510(k) K043545

Overview

The Microscan Dried Gram-positive Mic/Combo Panels With Daptomycin are in vitro diagnostic devices used for antimicrobial susceptibility testing of gram-positive bacteria. These panels contain dried antimicrobial agents including daptomycin at concentrations ranging from 0.03 to 16 mcg/ml to determine the minimum inhibitory concentration (MIC) of various antimicrobials.

The panels are incubated for 16-20 hours at 35°C ± 1°C in a non-CO2 environment and can be read either visually or with MicroScan instrumentation. This device is supplied as a single-use product and is classified under product code LRG with FDA 510(k) clearance K043545. The device is intended for use in microbiology laboratories to assist in the selection of appropriate antimicrobial therapy for patients with gram-positive bacterial infections.

AI-generated from registry data, 25 Sep 2026.Not verified by deviCERTS or the manufacturer

Regulatory status

as of 28 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK043545 Date17 Feb 2005ClearedStatusActive

Coverage

1 jurisdiction

United States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not known
  • Not covered

United States — FDA 510(k) Active

Recalls

1 recall · FDA

    • Terminated Z-0720-2021 FDA Class II initiated 2 Dec 2020

    Due to a customer report and internal investigation, it was confirmed that a portion of the affected product lot failed quality control (QC) for ATCC E. Faecalis 29212 versus daptomycin and it is a possibility to obtain false elevated MIC for clinical isolates with daptomycin even when quality control results are within specification.

Specification

510(k)

510(k) Number
FDA Product Code
LRG
Device Class
Class II
Regulation
21 CFR Part 866.1640
Advisory Committee
Microbiology
FDA Decision
SESE Substantially Equivalent

Other devices from Dade Behring, Inc.

See all devices from Dade Behring, Inc. →

Questions

  • What is the purpose of the Microscan Dried Gram-positive Mic/Combo Panels with Daptomycin?

    These are in vitro diagnostic devices used for antimicrobial susceptibility testing of gram-positive bacteria. They contain dried antimicrobial agents including daptomycin to determine the minimum inhibitory concentration (MIC) of various antimicrobials, helping clinicians select appropriate antimicrobial therapy for patients with gram-positive bacterial infections.

  • How are the Microscan Dried Gram-positive Mic/Combo Panels supplied and used?

    The panels are supplied as single-use products for microbiology laboratories. They are incubated for 16-20 hours at 35°C ± 1°C in a non-CO2 environment and can be read either visually or with MicroScan instrumentation to determine antimicrobial susceptibility.

  • What regulatory status does the Microscan Dried Gram-positive Mic/Combo Panels with Daptomycin have?

    The device has FDA 510(k) clearance K043545 and is classified under product code LRG. It is cleared as substantially equivalent to predicate devices for antimicrobial susceptibility testing of gram-positive bacteria in microbiology laboratories.

  • What is the concentration range of daptomycin in these panels?

    The panels contain daptomycin at concentrations ranging from 0.03 to 16 mcg/ml, which allows for determination of the minimum inhibitory concentration (MIC) of daptomycin against gram-positive bacteria to guide appropriate antimicrobial therapy selection.